Acquisition of VirtuOx completed for $140 million, with an annual revenue run rate of approximately $45 million, neutral to non-GAAP EPS in Q4.
Capital returned to shareholders totaled over $610 million through dividends and share repurchases.
Cash balance at quarter end was $1.2 billion with $668 million gross debt and $541 million net cash.
Cash flow from operations in Q4 was $539 million; capital expenditure was $31 million; depreciation and amortization totaled $64 million.
Free cash flow for fiscal year 2025 was $1.7 billion, supporting investments and shareholder returns.
Gross margin expanded by 230 basis points year-over-year to 61.4%, driven by procurement, manufacturing, logistics efficiencies, and favorable currency movements.
Net income increased by 22%, and non-GAAP diluted EPS rose by 23%, positively impacted by foreign exchange rates.
Operating profit increased by 19%, with operating margin improving to 35% from 33% the prior year.
ResMed reported 10% year-over-year revenue growth in Q4 FY 2025, reaching $1.35 billion, with 9% growth in constant currency terms.
A $34.8 million onetime tax benefit was recognized in Q2, primarily from the release of valuation allowances on R&D credits acquired in the Nevro deal.
The Nevro acquisition brought in $141.5 million of deferred tax assets, which are expected to generate cash tax savings over approximately 40-50 years.
The tax benefits improve the company's cash flow outlook and are part of the strategic integration and cost management efforts.
Adjusted EBITDA grew 9% year-over-year to $105.1 million, while GAAP net income was $12 million compared to $19.6 million in the prior year period.
Collegium Pharmaceuticals reported record quarterly revenue of $188 million, a 29% increase year-over-year, driven by strong performance across its portfolio including Jornay PM and the pain portfolio.
GAAP operating expenses increased 69% year-over-year, and non-GAAP adjusted operating expenses increased 104%, reflecting investments in Jornay commercialization.
Jornay PM generated record quarterly revenues of $32.6 million with prescriptions growing 23% year-over-year.
Operating cash flow was strong at $72.4 million, with $222 million in cash and equivalents at quarter-end.
The pain portfolio achieved record quarterly revenue of $155.4 million, up 7% year-over-year, with all three core pain medicines showing growth.
Dafinchi